Related Experiment Video
Updated: Aug 22, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary
Nicolette M S K J Ernst1, Harry Suryapranata, Kor Miedema
1Isala Klinieken, location Weezenlanden, Department of Cardiology, Zwolle, the Netherlands.
Insights
Platelet aggregation inhibition was suboptimal in ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI). High-dose tirofiban was the only agent to exceed 80% inhibition, though outcomes were not improved.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Platelet aggregation inhibition is crucial for predicting cardiac events post-PCI.
- Routine antiplatelet doses may be insufficient for STEMI patients undergoing PCI.
Purpose of the Study:
- To assess platelet aggregation inhibition in STEMI patients undergoing PCI with various antiplatelet agents and doses.
- To compare the efficacy of different antiplatelet strategies in this high-risk population.
Main Methods:
- 112 STEMI patients received clopidogrel and were randomized to abciximab, tirofiban, high-dose tirofiban, or no glycoprotein (GP) IIb/IIIa inhibitor.
- Platelet aggregation was measured pre-angiography, post-PCI, and at 1 and 6 hours post-PCI.
Main Results:
- Platelet aggregation inhibition was variable and generally suboptimal across all tested agents and dosages.
- Only high-dose tirofiban achieved mean periprocedural inhibition above 80%.
- No significant differences in angiographic outcomes (TIMI frame count, myocardial blush grade) were observed between groups.
Conclusions:
- Current antiplatelet strategies provide variable and suboptimal platelet aggregation inhibition in STEMI patients undergoing PCI.
- High-dose tirofiban demonstrated superior inhibition but did not correlate with improved angiographic outcomes.
- Further research is needed to optimize antiplatelet therapy for STEMI patients undergoing PCI.
Objectives:
To evaluate the extent of platelet aggregation inhibition in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), treated with different antiplatelet agents and dosages.
Background:
The extent of platelet aggregation inhibition is an independent predictor of major cardiac events after elective PCI. In STEMI patients undergoing PCI, routine dose of antiplatelet agents may be associated with less effective platelet aggregation inhibition.
Methods:
Patients were treated with clopidogrel before angiography and randomized to abciximab, tirofiban, high-dose tirofiban, or no glycoprotein (GP) IIb/IIIa inhibitor; GP IIb/IIIa inhibitor bolus, followed by maintenance infusion, was administered after angiography, but before PCI. Platelet aggregation inhibition was assessed before angiography, immediately after PCI, and 1 and 6 h afterwards.
Results:
The total study population consisted of 112 patients. Platelet aggregation inhibition was variable for individuals and suboptimal for all agents, particularly in the periprocedural period. Only with high-dose tirofiban, mean periprocedural platelet aggregation inhibition exceeded 80%. Angiographic parameters after PCI were not different between the groups. No relationship was found between the level of platelet aggregation and parameters of PCI success (Thrombolysis In Myocardial Infarction frame count and myocardial blush grade), after combining the data from all four groups studied.
Conclusions:
Platelet aggregation inhibition in STEMI patients undergoing PCI, treated with antiplatelet agents, is variable and suboptimal for all agents and dosages studied. Only with high-dose tirofiban, mean periprocedural platelet aggregation inhibition exceeded 80%. However, no relationship of platelet aggregation inhibition and angiographic outcome was found in this patient cohort.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Acute Coronary Syndrome I: Introduction